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Abstract
Background
The number of robotic assisted radical cystectomy (RARC) procedures is increasing
despite the lack of Level I evidence showing any advantages over open radical cystectomy
(ORC). However, several systematic reviews with meta-analyses including non-rando-
mised studies, suggest an overall benefit for RARC compared to ORC. We performed a
systematic review with meta-analysis of randomised controlled trials (RCTs) to evaluate
the perioperative morbidity and efficacy of RARC compared to ORC in patients with bladder
cancer.
Methods
Literature searches of Medline/Pubmed, Embase, Web of Science and clinicaltrials.gov
databases up to 10th March 2016 were performed. The inclusion criteria for eligible studies
were RCTs which compared perioperative outcomes of ORC and RARC for bladder can-
cer. Primary objective was perioperative and histopathological outcomes of RARC versus
ORC while the secondary objective was quality of life assessment (QoL), oncological out-
comes and cost analysis.
Results
Four RCTs (from 5 articles) met the inclusion criteria, with a total of 239 patients all with
extracorporeal urinary diversion. Patient demographics and clinical characteristics of
RARC and ORC patients were evenly matched. There was no significant difference
between groups in perioperative morbidity, length of stay, positive surgical margin, lymph
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node yield and positive lymph node status. RARC group had significantly lower estimated
blood loss (p<0.001) and wound complications (p = 0.03) but required significantly longer
operating time (p<0.001). QoL was not measured uniformly across trials and cost analysis
was reported in one RCTs. A test for heterogeneity did highlight differences across operat-
ing time of trials suggesting that surgeon experience may influence outcomes.
Conclusions
This study does not provide evidence to support a benefit for RARC compared to ORC.
These results may not have inference for RARC with intracorporeal urinary diversion. Well-
designed trials with appropriate endpoints conducted by equally experienced ORC and
RARC surgeons will be needed to address this.
Introduction
Radical cystectomy and lymphadenectomy remains the recommended curative treatment for
muscle invasive bladder cancer and recurrent high grade non-muscle invasive bladder cancer
[1]. In recent years, robotic assisted radical cystectomy (RARC) has become the surgical
approach of choice in a number of high volume institutions [2–4].
Minimally invasive surgery seeks to reduce post-operativemorbidity and allow an early
return to normal activity while replicating the principles of open surgery and maintaining
oncological equivalence [5]. The benefits of minimally invasive surgery in colorectal cancer is
supported by level one evidence. Patients who had laparoscopic colorectal cancer resections
had similar oncological outcomes, enhanced postoperative recovery, shorter hospital length of
stay (LOS) and lower use of parenteral narcotics with a similar post-operative complications,
mortality and hospital readmission rates [6].
Previous systematic reviews with meta-analyses were conducted to determine the benefits
for RARC, and concluded that patients undergoing RARC have a lower post-operativemorbid-
ity, a shorter LOS and higher lymph node yield compared to open radical cystectomy (ORC)
[7–10]. However, these reviews incorporated retrospective and prospective cohort studies
which are subject to significant bias. Furthermore, two more RCTs have since been published
after these four reviews, and the addition of these studies may aid in determining the benefits
of RARC over ORC. To date, there has been no systematic reviewwith meta-analysis which
includes data exclusively from RCTs of RARC versus open radical cystectomy (ORC).
Therefore, the primary objective of this systematic review is to compare RARC versus ORC
on perioperative and histopathological outcomes. Secondaryoutcomes include quality of life
assessment, oncological outcomes and cost analysis.
Methods
Search strategy and study selection
A systemic search of the literature was performed in MEDLINE/PubMed, Embase,Web of Sci-
ence and clinictrials.govdatabases up till 10th March 2016. The following keywords and MeSH
terms were used: (bladder cancer OR transitional cell carcinoma OR urothelial cell carcinoma
OR urinary bladder cancer OR urinary bladder neoplasmOR urinary bladder tumor OR uri-
nary bladder tumour OR urinary bladder carcinoma) AND (cystectomy OR cystoprostatect-
omy OR bladder resection) AND (robotic OR da vinci OR robotic-assistedOR robotic
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assisted) AND (open) AND (randomisedOR randomized). Only studies published in English
were included. All conference abstracts, review articles, editorials, comments, letters to the edi-
tor and duplicate records were excluded.
The inclusion criteria for eligible studies were: 1) RCTs and 2) comparisons betweenORC
and RARC for bladder cancer. The exclusion criteria were: 1) non-English studies and 2) con-
ference abstracts, literature reviews, editorials, comments, and letters to the editor. Abstracts
and full text articles for eligible studies were independently screened by two authors. When
there was a discrepancy, the study was discussedwith a third author. The PRISMA flowchart
and checklist is shown in Fig 1 and S1 Table respectively. Risk of bias for each study was
assessed by two authors independently using the Cochrane ‘risk of bias table’.
Data extraction and outcome of interest
The following data were extracted from studies which met the inclusion criteria:
Patient demographics. Age, gender, bodymass index (BMI), American Society of Anes-
thesiologists (ASA) score, type of urinary diversion, pathological T staging, previous pelvic or
abdominal surgery and use of neo-adjuvant chemotherapy (NAC).
Fig 1. Flow chart of studies identified, excluded and included.
doi:10.1371/journal.pone.0166221.g001
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Perioperative variables. Estimated blood loss (EBL), blood transfusion requirement, oper-
ative time, length of hospital stay (LOS), quality of life (QoL) assessment and 90-day postoper-
ative complications. Complications were classified according to the modifiedMemorial Sloan-
Kettering Cancer Center (MSKCC) Clavien-Dindo (CD) system [11]. Minor and major com-
plications were defined as CD I-II and CD III-IV respectively.
Oncological variables. Cystectomy histopathological tumour and nodal stage (according
to 2002 TNM classification) [12], positive surgical margins (PSM), mean lymph node yield and
positive lymph node status.
Statistical analysis
The meta-analysis was conducted using ReviewManager software v.5.3 (CochraneCollabora-
tion, Oxford, UK). The weightedmean difference (WMD) and odds ratio (OR) were used to
compare continuous and dichotomous variables respectively. For studies presenting continu-
ous data as median and range or interquartile range (IQR), mean and standard deviation was
calculated according to methodologydescribedby Hozo et al. [13].
Study heterogeneity was assessed for each outcome using Cochrane’s χ2 test, with p<0.10
indicating evidence of heterogeneity. Degree of heterogeneity was quantified using the I2 statis-
tic, with I225% indicating substantial heterogeneity. A random-effectmodel was used to
attempt to account for significant heterogeneity. Statistical significancewas set at p<0.05 in all
tests.
A sensitivity analysis was performed using R v3.2.4 (Lucent Technologies, New Jersey,
USA) using the metafor package. A ‘leave one out’ algorithmwas used to assess the influence
of each individual study. The meta-analysis was also repeated using risk ratios as the outcome
statistic instead of odds ratio.
Results
Characterisation of eligible studies
One-hundred and seventy-six citations were identified from the database search (Fig 1). After
screening of citations, 16 full text studies were reviewed and six manuscripts from five RCTs
were met the inclusion criteria [14–19]. No published data was available for one RCT which
closed early due to poor recruitment [19]. The remaining four RCTs contributed to 239
patients (RARC: 121, ORC: 118). Four RCTs reported perioperative complications [14–17],
three studies reportedQoL data [15, 17, 18], one study reported oncological outcomes [15] and
one performed cost analysis [17]. One of the four studies had a third group treated with laparo-
scopic cystectomy and this group was not included in the analysis [15]. A full risk of bias
assessment is shown in a ‘risk of bias table’ in S2 Table.
Patient demographics and clinical characteristics
Patient demographics and clinical characteristics are shown in Tables 1 and 2. There was no
baseline difference for RARC and ORC patients in age, sex, BMI, ASA and T-stage in all four
studies. Three studies excluded patients with extensive previous abdominal surgery and one
study did not specify this [16]. Similarly, data from three studies reported no difference in
NAC use and data was not available in one study [16].
Urinary diversion from the robotic group of all four RCTs were performed by an extracor-
poreal approach. More patients underwent ileal conduit urinary diversion (113 patients vs 86
patients) compared to neobladder, even though there were a similar number of neobladders
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were reconstructed between RARC and ORC groups (RARC: 42, ORC: 44). One study did not
report type of urinary diversion constructed [14].
Perioperative outcomes
Intraoperative outcomes: Estimated blood loss, blood transfusion rate and requirement
and operating time. Pooling data from 239 patients showed that EBL was significantly lower
in RARC group compared to ORC (p<0.0001) (Fig 2). Only one RCT with 40 cases, reported
blood transfusion rate and requirements and showed no significant difference in both median
units of blood transfused (RARC: 0 vs ORC: 2, p = 0.410) and requirements (RARC: 8/20 vs
ORC: 10/20, p = 0.410) [14]. Pooled data from all four studies suggested that RARC was associ-
ated with significantly longer operative times (WMD: 71.98 mins; 95% CI (15.89, 128.07);
p = 0.01) (Fig 3).
Postoperative complications: Length of stay, 90-day all complications, 90-day major
complications, 90-day mortality and complication type. Data extracted from all four stud-
ies did not show a significant difference between LOS when RARCwas compared to ORC
(WMD: -0.46 days; 95% CI (-1.34, 0.42); p = 0.30) (Fig 4). Pooled data from 239 patients did
not show a difference in all 90-day complications in the RARC and ORC groups (OR: 0.75;
Table 1. Characteristics of included studies.
First author
and
reference
Recruitment Country Primary end
point
Number of
patients, ORC/
RARC
Male sex,
ORC/
RARC
Age, median/
mean, ORC/
RARC
IC patients,
ORC/ RARC
NB patients,
ORC/ RARC
Match factors
Nix et al.
2010 [16]
April 2008- Jan
2009
USA Lymph node
yield
20/ 21 17/ 14 69.2/ 67.4 14/ 14 6/ 7 1,2,3,4,7,8
Parekh et al.
2013 [14]
July 2009- June
2011
USA Feasibility study 20/ 20 16/ 18 64.5/ 69.5 NA NA 1,2,3,4,5,6, 7
Bochner et al.
2015 [17]
March 2010-
March 2013
USA Perioperative
complication
58/ 60 42/ 51 65.0/ 66.0 23/ 27 35/ 33 1,2,3,4,5,6,7,8
Khan et al.
2016 [15]
March 2009-
July 2012
UK Perioperative
outcomes
20/ 20 18/ 15 66.6/ 68.6 17/ 18 3/ 2 1,2,3,4,5,6,7,8
1 = age, 2 = gender, 3 = BMI, 4 = ASA, 5 = previous abdominal surgery, 6 = neoadjuvant chemotherapy, 7 = clinical stage, 8 = diversion type, ORC: open
radical cystectomy, RARC: robotic assisted radical cystectomy, IC: ileal conduit, NB: neobladder
doi:10.1371/journal.pone.0166221.t001
Table 2. Analysis of patient demographics and clinical variables comparing RARC vs ORC.
Number of RARC/ ORC patients WMD/ OR (95% CI) P value X2 Study heterogeneity
df I2 (%) P value
Age 121/ 118 1.14 [-0.70, 3.61] 0.19 2.82 3 0 0.42
Proportion of males 121/118 1.15 [0.61, 2.14] 0.67 6.51 3 54% 0.09
BMI 100/ 98 -0.65 [-2.01, 0.70] 0.34 0.54 2 0 0.76
ASA I-II 36/31 1.46 [0.65, 3.30] 0.36 0.08 1 0 0.78
ASA III-IV 44/47 0.68 [0.30, 1.54] 0.36 0.08 1 0 0.78
Previous NAC 100/98 1.22 [0.63, 2.34] 0.56 0.81 2 0 0.67
Pathological T stage:pT2 85/85 0.75 [0.38, 1.49] 0.41 1.24 3 0 0.74
Pathological T stage:pT3 36/33 1.36 [0.67, 2.75] 0.40 1.20 3 0 0.75
BMI: body mass index, ASA: American Society of Anesthetics, NAC: neoadjuvant chemotherapy, ORC: open radical cystectomy, RARC: robotic assisted
radical cystectomy, WMD: weighted mean difference, OR: odds ratio, CI: confidence interval
doi:10.1371/journal.pone.0166221.t002
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95% CI (0.44, 1.28); p = 0.29) (Fig 5). Similarly, no significant difference was observed in
90-day major complications between both groups (OR: 1.11; 95% CI (0.55, 2.22); p = 0.77) (Fig
6). No difference was observed in 90-day mortality betweenRARC and ORC (OR: 0.32; 95%
CI (0.03, 3.00); p = 0.32). Wound complication was the only complication which was signifi-
cantly lower in RARC compared to ORC (OR: 0.23; 95% CI (0.03, 0.88); p = 0.03) (Table 3).
Histopathological variables: Positive surgicalmargin (PSM), lymph node count and pos-
itive lymph node status. Data from four studies that accessed PSM status showed no signifi-
cant difference between the RARC and ORC groups (OR: 0.98; 95% CI (0.29, 3.23); p = 0.97)
(Fig 7). There was also no significant difference between lymph node yield (WMD: 3.89; 95%
CI (-1.55, 9.33); p = 0.16) (Fig 8) and positive lymph node status (WMD: 0.84; 95% CI (0.48,
1.47); p = 0.54) (Fig 9) between RARC and ORC groups. Bochner et al. was the only study to
divide lymph node dissection (LND) to standard and extended [17]. While only lymph node
yield of standard dissectionwas used for meta-analysis to avoid introducing heterogeneity in
the analysis, no difference in lymph node yield between RARC and ORC was observed in an
extended LND (p = 0.5).
Quality of life outcomes
Although three studies evaluated the QoL postoperatively, different questionnaires were used,
hence pooled analysis of data was not possible [15, 17, 18]. Messer et al. used the Functional
Assessment of Cancer Therapy–Vanderbilt Cystectomy which were completed 3-monthly for
12 months [18], Bochner et al. used the European Organisation for Research and Treatment of
Cancer (EORTC) QLQ-C30 questionnaire which was completed at 3 and 6 months postopera-
tively [17], while Khan et al. used the Functional Assessment of Cancer Therapy-General,
Functional Assessment of Cancer Therapy-Bladder and Trial Outcome Index questionnaire
which was completed at a mean of 8 months postoperatively [15]. However, all studies con-
cluded that there was no significant difference in QoL between the RARC and ORC groups.
Oncological outcomes
Of the four studies, only one study reported oncological outcomes with no significant differ-
ence in recurrence free survival (RFS) (RARC: 73.6%; ORC: 89.0%; p = 0.5), cancer specific
Fig 2. Forest plot and meta-analysis of blood loss (10ml).
doi:10.1371/journal.pone.0166221.g002
Fig 3. Forest plot and meta-analysis of operating time (mins).
doi:10.1371/journal.pone.0166221.g003
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survival (CCS) (RARC: 100%; ORC: 100%; p = 1.0) and overall survival (OS) (RARC: 95%;
ORC: 100%; p = 0.1) [15].
Cost analysis
Only one study performed cost analysis based on Medicare reimbursement [17]. Patients who
had RARCwith neobladder reconstruction generated an average additional average cost of
$3,920 compared to ORC patients (p< 0.0001) whereas patients who had an ileal conduit fol-
lowing RARC incurred an additional average cost of $1,740 compared to ORC (p< 0.05). Lon-
ger operating time attributed to 98% and 69% of additional cost in ileal conduit and
neobladder patients respectively.
Heterogeneity of studies
Significant heterogeneity was detected between studies in lymph node yield and operating
time. This is likely attributed to differences in surgical technique and experience between sur-
geons. Analysing pooled data using the random-effectmodel was performed to reduce the
effect of between-study heterogeneity.
Sensitivity analysis
The ‘leave-one-out’ sensitivity analysis demonstrated that none of the conclusions would
change if any one study was removed for each outcome variable. The full results of this are con-
tained in the S1–S8 Figs. Repeating the summary estimates using risk ratio instead of odds
ratio for the dichotomous variables; all complications, major complications, positive surgical
margins and lymph node status, again revealed no change to the findings.
Discussion
This is the first systematic review and meta-analysis of randomised controlled trials comparing
the outcomes of RARC and ORC. Previously, there have been four other systematic reviews on
Fig 4. Forest plot and meta-analysis of length of stay.
doi:10.1371/journal.pone.0166221.g004
Fig 5. Forest plot and meta-analysis of all complications.
doi:10.1371/journal.pone.0166221.g005
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this topic, however these included both retrospective and prospective comparative studies
which were at high risk of selection, reporting and publication bias [7, 8, 10, 20]. These meta-
analyses have concluded that RARC is associated with lower perioperative complications,
reduced LOS, higher lymph node yield, lower transfusion requirement and equivocal PSM.
The current meta-analysis comprising of pooled data with 239 patients from four RCTs does
not support the conclusions from non-RCTmeta-analysis [7, 8, 10, 20]. The results of the cur-
rent meta-analysis show that RARC is associated with lower EBL, lower wound complications
rate and longer operating times. However, no significant difference is observed in 90-day peri-
operative complications, LOS, lymph node yield, PSM and QoL. A sensitivity analysis demon-
strating that neither choice of statistical outcome measure nor any individual RCT impacted
on the results supports the validity of the conclusions in this report.
Comparisons betweenmorbidity rates reported for individual surgical series is often chal-
lenging due to significant variation in surgical technique, prior operative experience and docu-
mentation of complications [21]. 90-day complication rates of between 30% and 77% have
been reported for RARC with extracorporeal urinary diversion [22]. To standardise reporting
methodology for radical cystectomy, a modifiedClavien-Dindo classification has been pro-
posed [11]. All RCTs used either traditional Clavien-Dindo or modified classification system to
standardise reporting.
In this analysis, we did not find a significant difference in 90-day perioperative complica-
tions between studies. A recent study analysed complications following RARC with intracor-
poreal urinary diversion in 134 cases and found that the majority of ClavienIII
complications can be attributed to a surgical cause which may be related to surgeon experience
[23]. In our meta-analysis of operating time, there was significant heterogeneity observed
which may reflect a variation in surgical experience in RARC. None of the RCTs reported prior
surgical experience for either RARC or ORC, and therefore it was difficult to determine this.
Although the learning curve to achieve minimal perioperative complications is yet to be
Fig 6. Forest plot and meta-analysis of major complications.
doi:10.1371/journal.pone.0166221.g006
Fig 7. Forest plot and meta-analysis of positive surgical margin.
doi:10.1371/journal.pone.0166221.g007
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defined, a minimum of 30 cases is suggested to achieve adequate lymph node yield and PSM
[24] while experience of more than 100 cases has been put forward as a minimum to be consid-
ered very experienced [25]. In robotic assisted laparoscopic prostatectomy (RALP), periopera-
tive complications continue to improve and plateau after 150 cases while improvements in
urinary incontinence and sexual function outcomes were observeduntil after 600 cases [26,
27]. Hence, these results may not be as heterogeneous if RARC was performed by experienced
surgeons.
Patients undergoing radical cystectomy are often older, smoke tobacco and have co-morbid-
ities such as cardiovascular and renal dysfunction,making them susceptible to perioperative
complications. A single arm study in RARCwith intracorporeal urinary diversion reported
that poor cardiorespiratory fitness measured by cardiopulmonary exercise testing did not pre-
dict 30-day perioperative complications [28]. In colon cancer, a large RCT of minimally inva-
sive versus open colectomy did not show differences in 60-day complications but did report
significantly shorter LOS (p0.001) and lower use of opiate based analgesia (p0.001) [6].
Hence, it has been hypothesised that RARC will reduce perioperativemorbidity or at the very
least shorten LOS compared to ORC which is contrary to our findings.While there is no RCT
comparing RALP with open radical prostatectomy (ORP), RALP has now succeededORP as
the most common surgical approach for radical prostatectomy with excellent perioperative
Table 3. Analysis of perioperative complications according to Memorial classification.
Complications Number of RARC/ ORC patients WMD/ OR (95% CI) P value X2 Study heterogeneity
df I2 (%) P value
Bleeding 121/ 118 1.27 (0.30, 5.29) 0.75 0.41 1 0
Cardiac 121/ 118 1.06 [0.48, 2.32] 0.88 0.99 3 0 0.80
Gastrointestinal 121/ 118 0.66 [0.40, 1.10] 0.11 1.34 3 0 0.72
Genitourinary 121/ 118 0.81 [0.27, 2.45] 0.71 4.92 3 39 0.18
Infectious 121/ 118 1.18 [0.80, 1.73] 0.40 0.80 3 0 0.85
Miscellaneous 121/ 118 0.55 [0.12, 2.52] 0.44 0.15 1 0 0.70
Neurologic 121/ 118 1.38 [0.42, 4.58] 0.60 2.30 3 0 0.51
Pulmonary 121/ 118 0.32 [0.03, 3.01] 0.32 N/A N/A N/A N/A
Surgical 121/ 118 1.40 [0.23, 8.64] 0.72 1.22 2 0 0.54
Thromboembolic 121/ 118 1.24 [0.43, 3.52] 0.69 0.75 2 0 0.69
Wound 121/ 118 0.23 [0.06, 0.88] 0.03 0.02 1 0 0.89
Death 121/ 118 0.32 [0.03, 3.00] 0.32 0.00 1 0 1.00
RARC: robotic assisted radical cystectomy, ORC: open radical cystectomy, WMD: weighted mean difference, OR: odds ratio, CI: confidence interval, NA:
not applicable
doi:10.1371/journal.pone.0166221.t003
Fig 8. Forest plot and meta-analysis of lymph node yield.
doi:10.1371/journal.pone.0166221.g008
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outcomes [29]. In comparison to previous meta-analyses, the current review did not show a
reduction in LOS betweenRARC and ORC.
Urinary diversion reconstruction, accounts for the majority of complications following radi-
cal cystectomy [30]. All previous systematic review and meta-analyses included in this meta-
analysis performed urinary diversion reconstruction using an extracorporeal approach. The
requirement for a mini laparotomy for the urinary diversion reconstruction has been postu-
lated to negate potential perioperative benefits of a minimally invasive approach and with
intracorporeal urinary diversion gaining popularity, the question remains whether the
approach to diversion reconstructionwill have an impact on perioperative outcomes.
All previous systematic reviews and meta-analyses including our current review consistently
report that RARC is associated with a significantly lower EBL translating to a lower blood
transfusion rate. This could be attributed to a more precise and controlled dissection using the
robotic platform as well as pneumoperitoneum.No RCT has been designed to measure the
effects of perioperative transfusion on either functional recovery or oncological outcome in
cystectomy. Evidence that blood transfusion is associated with increased 30-day morbidity and
mortality stems from the analysis of 10,100 patients who had non-cardiac surgery [31]. In radi-
cal cystectomy, a study of 1,490 consecutive cases showed that perioperative blood transfusion
was associated with increased cancer specificmortality and overall mortality [32]. These small
but highly significant effectsmay require a large sample size to uncover which would be very
difficult to prove in a RCT and to alter practice would be based on inference.
PSM and lymph node yield are indicators of surgical quality. The presence of soft tissue
PSM in particular reduces 5-year cancer specific survival to 32% (95% CI: 19–54) from 72%
(95% CI: 69–75) [33]. In an analysis of 4,410 ORC patients with the overall incidence of a PSM
was 6.3%, PSM was associated with higher pathological T stage; PSM for pT1, pT2, pT3 and
pT4 was 1.8%, 2.3%, 7.6% and 24.0% respectively [34]. This meta-analysis shows no significant
difference in PSM between RARC and ORC however only 18.0% of patients in the meta-analy-
sis werepT3 disease. In a series of 184 ORC and RARC cases, no difference in PSM have
been reported betweenRARC and ORC [2].
Retrospective studies have shown that a higher lymph node yield of at least 8 is associated
with cancer specific survival even in node negative disease [35]. Comparing lymph node yield
is confounded by factors such as the use of NAC, pathological stage of disease, surgeon and
method of pathological evaluation. None of the RCTs included an adjustment for case mix and
the meta-analysis did not show a difference in lymph node yield betweenRARC and ORC. The
Southwest OncologyGroup (SWOG) S1011 (NCT01224665) trial is still ongoing and will
address the issue if extended LND is necessary. Three of the four RCTs performed a standard
Fig 9. Forest plot and meta-analysis of lymph node positive status.
doi:10.1371/journal.pone.0166221.g009
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template while Bochner et al. used both standard and extended LND with comparable lymph
node yield suggesting that the quality of LND in RARC is equivocal to ORC [17].
It was not possible to pool QoL data for this analysis as QoL was assessed by different tools
and at different time points. Among the three RCTs to date, there has been no difference in
QoL reported for RARC compared to ORC. In the colorectal literature, patients treated with
laparoscopic surgery showed better QoL in the early postoperative phase but this was no longer
evident in longer term follow up [36]. However, a recent RCT comparing open retropubic
prostatectomy with robotic assisted radical prostatectomy failed to show any significant differ-
ence between early functional outcomes as well as quality of life measured at 12 weeks postop-
eratively [37]. All three RCTs assessedQoL between 3–8 months post-surgery. It is possible
that any potential gain from a minimally invasive approach may have been undetected. A fur-
ther limitation will be the sample size for individual studies. A health economic analysis has
not been conducted by any of the RCTs however, one study did perform a cost analysis and
attributed higher cost for RARC to longer operating time [17].
Limitations of this systematic reviewwith meta-analysis include the small sample size for
pooled data. In addition, each of the RCTs were conducted at a single institution. This is evi-
dent in operating time heterogeneity and might reflect individual surgeon experience rather
than surgical technique. To date all RCTs have either been feasibility studies, have closed before
planned recruitment or were designed to measure surrogate endpoints. The pooled data set
comprised 239 cases in total, and the systematic reviewwith meta-analysis was not conducted
on individual patient data and a test for heterogeneity has highlighted that surgical experience
may have influenced the results. A further consideration is the conversion from a truly mini-
mally invasive approach to open surgery for urinary diversion reconstructionwhich could con-
found the benefits of minimally invasive surgery.
Conclusion
This study is the first systematic reviewwith meta-analysis to include data from only RCTs of
ORC versus RARC. Unlike previous systematic reviews with meta-analyses, which have
included observational data, our results do not show a benefit for RARC compared to ORC.
There are significant issues with the trials which have been conducted in RARC which may
influence the outcome and integrity of the meta-analysis at this time. RARC with intracorpor-
eal urinary diversion remains an evolving technique and high quality RCTs will be required to
determine benefit. In addition, RCTs should be performed by equally experiencedORC and
RARC surgeons. For the present, the role of RARC and whether the technique can challenge
ORC as the standard of care remains unanswered.
Supporting Information
S1 Fig. Leave one out sensitivity analysis for outcome blood loss (10 ml).
(TIF)
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